ACXP News and Press, Acurx Pharmaceuticals Inc. From 02/02/24

NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street is airing its national TV show on the FOX Business Network on Monday, February 5, 2024, at 10:30 PM. New to The Street's 553rd episode features the following five (5) corporate interviews: 1). Vacation...

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street TV announces the broadcasting of its business show airing on Bloomberg TV as sponsored programming tonight, Thursday, February 1, 2024, at 9:30 PM PT. New to The Street's TV episode #552 will air the f...

Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients PR Newswire In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of ...

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street , a national TV show, announces episode 551, airing on the FOX Business Network on Monday, January 29, 2024, at 10:30 PM PT. New to The Street's 551st episode line-up features the following Five (5) Co...

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024 PR Newswire STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmace...

2024-01-22 12:04:50 ET Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expec...

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- FMW Media Works Corp.'s New to the Street, a nationally broadcasted business television production, announces airing episode 550 on the FOX Business Network , Monday, January 22, 2024, at 10:30 PM PT. New to The Street's 550 th TV epis...

2024-01-18 08:24:12 ET More on pre-market losers & stocks. Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript Psyence's unit signs deal for up to $10M in funding via issuance of convertible notes Dawson James sees Cytosorbents' Cytosorb as approvabl...

2024-01-17 11:49:53 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment ELAB, KIND and RLX among pre-market losers Acurx spikes af...

2024-01-17 10:00:18 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Health stocks to watch this earnings season as sector poised for resurgence Seeking Al...